- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Biotech Graveyard | ||
| Fr | Cash-strapped Nanobiotix finds fresh way to source cash from J&J-partnered cancer drug | ||
| Fr | 4DMT eyes $420M deal from Otsuka, with cash aimed at retinal gene therapy's phase 3 plans | ||
| Do | Eli Lilly sidelines midstage prospect in another pain pipeline pivot | ||
| Do | BMS culls 2 clinical programs, one from Mirati and another from Exscientia | ||
| Do | Inflammation biotech Evommune prices IPO after MapLight's $250M debut | ||
| Do | Sensei drops sole clinical-stage cancer drug, plans layoffs to conserve remaining cash | ||
| Do | Takeda drops AstraZeneca-partnered neurological program after phase 2 failure | ||
| Do | Novo makes bombshell $6.5B counteroffer to Pfizer's acquisition of obesity biotech Metsera | ||
| Do | FDA places Intellia phase 3 CRISPR trials on hold over raised liver enzymes | ||
| Do | Boehringer returns to Kyowa Kirin with €640M pact for preclinical autoimmune molecule | ||
| Do | Roche pens $1B biobucks deal for Chinese company's respiratory disease bispecific | ||
| Mi | Genentech says goodbye to 118 employees in third HQ layoff round of the year | ||
| Mi | AbbVie halts development of Dragonfly cancer asset midflight | ||
| Mi | Novartis drug reduces Sjögren's activity, patient burden in late-stage trials despite notable placebo effect | ||
| Mi | Regeneron pledges more than $1B biobucks for ModeX multispecific antibodies | ||
| Mi | Kyverna links CAR-T to improved autoimmune outcomes in small trial | ||
| Mi | GSK abandons hopes for CD226 cancer therapies, dropping remaining phase 2 assets | ||
| Di | Eli Lilly and Nvidia team up to build 'most powerful' supercomputer in pharma | ||
| Di | Edesa claims survival data win for phase 3 respiratory failure trial | ||
| Di | Aldeyra shuffles RASP pack, dropping and swapping assets in response to data | ||
| Di | Incyte scraps BET inhibitor against backdrop of safety concerns for the drug class | ||
| Di | GSK pens $745M deal for phase 1 drug that hits sweet spots of COPD, oligonucleotides | ||
| Mo | 2025 M&A up in value and deal count after year of 'conservatism and recovery': Leerink Partners | ||
| Mo | Intellia pauses phase 3 CRISPR trials after patient is hospitalized |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .